Evolving Roles of Fluorodeoxyglucose and Sodium Fluoride in Assessment of Multiple Myeloma Patients: Introducing a Novel Method of PET Quantification to Overcome Shortcomings of the Existing Approaches.
PET with fluorodeoxyglucose and sodium fluoride (NaF) radiotracers has shown a great promise in assessing patients with multiple myeloma (MM). However, the standardization of PET/computed tomography scans interpretation in patients with myeloma in clinical practice is still debatable. This article reviews available data regarding the use of fluorodeoxyglucose and NaF PET in patients with MM. Introduced is a novel method of PET quantification as applied to patients with MM. A new concept for PET-based evaluation of patients with MM is also discussed: dual time point imaging. Finally, the role of NaF in assessment of cardiovascular complications of MM is described.